Global Search

Hide Filters

Showing 1672 results

Press release / May 30, 2018

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (…
Press release / Jan 08, 2015

Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA

Pivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant…
Press release / Jan 16, 2018

Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients

Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1]…
Press release / Oct 23, 2015

Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis

Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of…
Press release / Nov 23, 2015

Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis

Cosentyx is the first and only IL-17A inhibitor from a new class of medicines shown to treat two of the most common inflammatory joint conditions in Europe[1] Cosentyx shows rapid and…
Press release / Jul 24, 2015

Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder

If approved, Revolade would be the first treatment option in its class in the EU for certain patients with SAA Approximately 40% of SAA patients unresponsive to initial immunosuppressive…
Press release / Feb 23, 2015

Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma

Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median…
Press release / Apr 17, 2018

Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures

The LIBERTY trial studied patients with episodic migraine who had failed 2 to 4 prior treatments, a uniquely difficult-to-treat population often excluded from migraine prevention trials …
Press release / Aug 24, 2017

Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Approval is based on pivotal MONALEESA-2 trial, which showed Kisqali plus letrozole reduced risk of disease progression or death by 43% versus letrozole alone[1] Kisqali plus letrozole…
Press release / Oct 30, 2017

Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA

Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting[1],[2] Structural disease progression is a…

‹ Previous page
1
…
28
29
30
31
32
33
34
…
168
› Next page